William K. Oh, MD

Articles

Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate Cancer

May 5th 2020

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

Dr. Oh on Adapting the PRINT Trial Model to Other Settings in Prostate Cancer

April 30th 2020

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate Cancer

April 23rd 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Dr. Oh on the Role of Radiopharmaceuticals in mCRPC

April 8th 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Dr. Oh on Results From the PRINT Trial in mCRPC

March 31st 2020

William K. Oh, MD, sheds light on the results of the phase II PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Design and Results of the PRINT Trial in Castration-Resistant Prostate Cancer

March 12th 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Remaining Challenges With Prostate Cancer Treatment

February 27th 2020

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Dr. Oh on Targeted Treatment in Metastatic Castration-Resistant Prostate Cancer

February 8th 2020

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, and deputy director of The Tisch Cancer Institute, discusses targeted treatment in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Oh on the ENZAMET Trial in mHSPC

January 30th 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Remaining Challenges in mHSPC

December 7th 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC

November 8th 2019

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

The Case for Platinum Therapy in Prostate Cancer

May 2nd 2018

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

Dr. Oh Discusses Immunotherapy in Prostate Cancer

January 13th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the role of immunotherapy for patients with prostate cancer.

Dr. Oh on the Hormone-Sensitive Setting in Prostate Cancer

January 6th 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the hormone-sensitive setting of prostate cancer.

Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC

December 16th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel (Taxotere) in patients with metastatic castration-resistant prostate cancer.

Dr. Oh Discusses Choosing Abiraterone in Prostate Cancer

December 14th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, explains when he would choose abiraterone acetate (Zytiga) for patients with prostate cancer.

Dr. Oh on AR-Targeted Therapy and Chemotherapy for CRPC

June 2nd 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Dr. Oh on the Sequencing of New Therapies for Prostate Cancer

February 24th 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).

Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer

February 22nd 2017

William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.